According to the current analysis of Reports and Data, the global Leishmaniasis Treatment market was valued at USD 124.4 Million in 2020 and is expected to reach USD 237.7 Million by the year 2028, at a CAGR of 8.40%. A disease outbreak takes place when a disease escalates by a higher number than expected in a region or during a season. An outbreak may occur in one community or even extend to several countries altogether. There was a time when people in all countries and on all continents remain chronically vulnerable to infectious diseases, known and unknown. Leishmaniasis was the neglected tropical disease (NTD) that has threatened the people worldwide as per the WHO. Leishmaniasis is a major complex of protozoal vector-borne diseases that affects both humans and animals. The disease is caused by different species of Leishmania, and it is manifested by three major clinical forms named as cutaneous, mucosal and visceral leishmaniasis. Leishmaniasis is transmitted by the bite of infected female sand flies. In each of these forms, infection ranges from causing no symptoms (asymptomatic infection) to severe, even life-threatening complications.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC])@ https://www.reportsanddata.com/sample-enquiry-form/2153
According to the National Organization of Rare Disorders, only a small percentage of people infected by Leishmania parasites will go on to actually develop the disease. There is uneven global distribution of the disease often because of the various distribution pattern of the parasite, the vector and the reservoir host species. Efforts to increase visceral leishmaniasis surveillance, vector control, diagnosis, and treatment are making important progress all across the world. In 2012, WHO launched an action plan for reducing the impact of Neglected Tropical Diseases (NTDs), including visceral leishmaniasis. Leishmaniasis is seldom encountered in the United States.
Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.reportsanddata.com/report-detail/leishmaniasis-treatment-market
Increasing affordability of drugs and therapeutics, growing awareness regarding advanced surgical and treatment approaches, increasing number of government programs to support healthcare facilities and medical treatments, growing population suffering from chronic and lifestyle induced diseases, and rising level of disposable income to drive market growth over the forecast period. The pharma and healthcare industry has witnessed significant revenue growth with the emergence of COVID-19 pandemic. Increasing regulatory approvals, robust pipeline of drugs and therapeutics, growing RD activities, and rising investment to accelerate clinical research are some other factors driving market growth.
Request a customization of the report @https://www.reportsanddata.com/request-customization-form/2153
Further key findings from the report suggest
- Introduction of new chemical entity will drive the leishmaniasis treatment market. According to the data of Drugs for Neglected Diseases initiative (DNDi), in 2017 two new chemical entities labelledDNDI-6148 and DNDI-0690 are introduced into the preclinical development stage to treat visceral and cutaneous leishmaniasis in 2016. Immunomodulator- CpG-D35, is also in a pre-clinical development stage, which would further be used as an adjunct along with main drug therapy to treat cutaneous leishmaniasis. These technical advances have the potential to transform new treatment therapy in upcoming future, in turn driving the growth of leishmaniasis treatment market during the forecast period.
- In the pathological testing segment, serological testing is expected to be the fastest growing segment which is expected to grow at a CAGR of 9.4% during the forecast period due to the global rise in the infectious disease outbreaks including include Leishmaniasis in developing nations. The outbreak of epidemic disease due to the malnutrition, population displacement, poor housing, a weak immune system and lack of financial resources are responsible for the market growth across the globe.
- Visceral Leishmaniasis holds the CAGR of 9.2% which is highest in the disease segment of leishmaniasis treatment market. According to the data of WHO, an estimated 50 000 to 90 000 new cases of Visceral Leishmaniasis occur worldwide each year out of which only an estimated 25–45% are reported to WHO. In 2017, more than 95% of new cases were reported to WHO which mainly occurred in 10 countries Bangladesh, Brazil, China, Ethiopia, India, Kenya, Nepal, Somalia, South Sudan and Sudan
- Europe is the second largest regional segment with the market share of 28.4% in 2018, due to the increased awareness of availability of different therapies and drugs for the treatment and rising awareness about innovations and advancements in Leishmaniasis treatment in pharmaceutical molecules, coupled with increasing incidences of target diseases across the world
- North America is expected to account for the largest market share of 2% of the Leishmaniasis treatment market, owing it to the prevalence of unhealthy lifestyle, high number of target diseases, rise in number of product approval by FDA, ongoing clinical trials, and favorable government regulations scenario contributing to the development of healthcare and therapeutics
- Visceral Leishmaniasis is expected to have the largest market share of 46.8% during the forecast period. According to the WHO, Visceral leishmaniasis (VL) is the world’s second-deadliest parasitic disease, after malaria. Key market players are collaborating with several government and private agencies to rise for the cause. For instance, Gilead is donating 445,000 vials of AmBisome to the World Health Organization over 5 years which is a leading brand being used for the treatment of leishmaniasis.
- Key participants Sanofi S.A., Sequus Pharmaceuticals Inc., Paladin Labs Inc., Enzon Pharmaceuticals Inc., Gland Pharma Limited, Gilead Life sciences and Lifecare Innovations Private Limited.
For the purpose of this report, Reports and Data has segmented the Leishmaniasis Treatment market on the basis of Disease type, pathological tests, therapy type, end use and region:
Disease Type (Revenue, USD Million; 2018–2028)
- Cutaneous Leishmaniasis
- Diffuse Cutaneous Leishmaniasis
- Mucocutaneous Leishmaniais
- Mucosal Leishmaniasis
- Visceral Leishmaniasis
Pathological tests (Revenue, USD Million; 2018–2028)
- By Serological Tests
- Direct Agglutination Test
- Indirect Immunofluorescent Antibody test (IFAT)
- Enzyme Linked Immunosorbent Assay (ELISA)
- Others
- Parasitological Evaluation
- Punch Biopsy
- Bone Marrow Biopsy
- Others
- DNA- Based Methods
- Nucleic Acid Hybridization
- Polymerase Chain Reaction (PCR)
- Immunological Methods
- Others
Therapy type (Revenue, USD Million; 2018–2028)
- By Drug Therapy
- Pentavalent Antimonials
- Sodium Stibogluconate
- SSG Meglumine antimoniate
- Antifungal
- Antibiotics
- Amphotericin B
- Liposomal amphotericin B
- Miltefosine
- Paromomycin
- Pentamidine
- By Non-Drug Therapy
- Cauterization
- Surgical Excision
- Cryotherapy
- Pentavalent Antimonials
End Use Revenue, USD Million; 2018–2028)
- Hospitals
- Clinics
- Diagnostic Laboratory
- Others
Regional Outlook (Revenue, USD Million; 2018–2028)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Spain
- France
- Italy
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Middle East and Africa (MEA)
Press Release Available@ https://www.reportsanddata.com/press-release/global-leishmaniasis-treatment-market
Key Questions Address in the Report:
- What is the growth rate of the Leishmaniasis Treatment Market? What is the market size the Leishmaniasis Treatment Market is expected to reach by 2028?
- What are the key growth driving and restraining factors of the Leishmaniasis Treatment Market?
- Who are the prominent players operating in the market? What are the key strategies adopted by these companies?
- What are key opportunities and growth prospects of the Leishmaniasis Treatment Market over the forecast period?
- Which region is expected to show significant growth in the coming years?
- Which application segment is expected to be the most lucrative over the forecast period?
Explore More Industry Research by Reports and Data:
Thank you for reading our report. Please connect with us to know more about the report or for requesting customization of the report. Our team will ensure the report is best suited to meet your requirements.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Read the innovative blog at https://www.reportsanddata.com/blogs
Check out our upcoming research report at https://www.reportsanddata.com/upcoming-reports
For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update: https://www.youtube.com/channel/UChLqKTFLm6sVBLEUjnadIhQ/video
